Some new hope for many patients with Lung cancer.
Doctors have found new ways to use some immune-boosting drugs to fight lung cancer.
In one, scientists at New York University conducted a study involving more than 600 patients with advanced lung cancer.
Reliance Jio said to offer HD channels for Rs 400 via JioHomeTV
After taking over the telecom and feature phone segment, Reliance Jio is now apparently planning to disrupt the DTH space. The report citing sources adds that Jio will launch the JioBroadcast service in the next few weeks.
The study results apply only to patients whose lung cancer does not begin in the squamous cells (or surface lung cell layer) and who also lack certain genetic mutations. Similarly, the new drug known as checkpoint inhibitors allows the immune system of the patient in order to destroy the deadly cancerous cells. They were picked at random to receive either chemotherapy plus immunotherapy, or chemotherapy plus a placebo, with two-thirds receiving the combination that included immunotherapy.
But patients in the immunotherapy group had more kidney problems, more immune-related adverse events and were more likely to stop treatment because of side effects. The most common side effects were nausea, anemia and fatigue and in both groups about 65% of patients experienced severe side effects.
Chief of Medical Oncology, Dr. Roy Herbst from the Yale Cancer Center said that, "I've been treating lung cancer for 25 years now, and I've never seen such a big paradigm shift as we're seeing with immunotherapy".
Mark Zuckerberg testifies before Congress
Also, it is predicted that they had produced around 80,000 Facebook posts over the course of two years according to CNBC. Many websites and apps use Facebook services to make their content and ads more engaging and relevant.
Cancer patients should be given immunotherapy as the first line of treatment following the results of "game-changing" trials, charities say. "I only treat lung cancer and I've been doing that for about 20 years".
But the benefits for Opdivo and Yervoy lasted less than two months on average.
"What we look at in these trials is overall survival - how long patients live - and we look at a number called the median survival - how long 50% of patients live", said Gomez.
Several States Complain Of A Cash Crunch, Residents Worried
Despite the currency flow going back to the pre-demonetisation levels, people are facing difficulty in withdrawing cash from ATMs. The Government has formed a state-wise committee and RBI also formed a committee to transfer currency from one state to other.
The estimated survival after a year was 69 per cent in those taking the immunotherapy drugs compared to 49 per cent who only had chemotherapy.